BSE filing, NSE: AGARWALEYE. Summary written from the filing by ALFA Finder's alert engine.
Dr. Agarwals Health Care Ltd: key numbers
- Share price
- ₹511.70
- Market cap
- ₹16,222 Cr
- Revenue (annual)
- ₹2,080 Cr
- Net profit (annual)
- ₹133.2 Cr
- P/E (TTM)
- 109.3×Sector 54.5×
- Promoter holding
- 32.33%-0.01% QoQ
- FII holding
- 49.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Agarwals Health Care Ltd
All →Dr. Agarwals Health Care Employee Stock Options
Dr. Agarwal's Health Care allotted 54,728 equity shares to employees on exercise of ESOP 2022 options. Paid-up capital rose to 31,70,99,111 shares, with no cash consideration stated.
Dr. Agarwals Health Care Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%), network-led growth; India EBITDA margin flat near 28%.
Dr. Agarwals Health Care Management Change
Dr Agarwals Health Care reports Mr. Amar Agarwal's redesignation from Chairman and Non-Executive Director to Executive Director, effective 1 November 2026. The change was approved at a board meeting held on 5 November 2026.
Dr. Agarwals Health Care Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹655 Cr (+31.4% YoY) and PAT ₹57 Cr (+55.8%). H1 FY27 revenue ₹1,269 Cr (+28.7%), PAT ₹112 Cr (+50.1%). Strategy is aggressive facility expansion, with 65 FY27E additions.
Dr. Agarwals Health Care Financial Results
Dr. Agarwal's H1 FY27 revenue rose 28.7% to Rs 1,269 crore; PAT rose 50.1% to Rs 112 crore. Amar Agarwal's executive chairman appointment awaits postal ballot approval.
Dr. Agarwals Health Care Board Meeting Date
Dr. Agarwal's Health Care schedules a board meeting on November 5, 2026 to consider Q2 results. An earnings call follows at 6:30 PM IST that day.
Other other announcement announcements
All →Fundviser Capital (India) Other Announcement
Fundviser Capital's quarterly Regulation 32 statement confirms no deviation in use of preferential warrant proceeds. Funds utilised total ₹38.10 Crore against ₹79.44 Crore raised.
Austere Systems Other Announcement
Austere Systems appointed EquiBridgeX Advisors as its Investor Relations and Public Relations agency effective November 5, 2026. The filing states no fees or financial terms.
Kiri Industries Other Announcement
Kiri Industries filed the Crisil monitoring agency report for the quarter ended September 30, 2026. The report covers utilisation of preferential warrant issue proceeds with no deviations.
Sahajanand Medical Technologies Other Announcement
Sahajanand Medical Technologies appointed Amit Jaste & Associates as Secretarial Auditor for 60 months, effective 5 November 2026. Approved at the same-day board meeting.
- Execution
- 60 months
Span Divergent Other Announcement
Span Divergent approved leasing Ahmedabad property to material subsidiary Dryfruit Factory LLP. Rent is capped at ₹3 lakh monthly under an arm's-length related-party transaction.
Cello World Other Announcement
Cello World's QIP monitoring report shows no fund deviation for the quarter ended September 2026. Object 1 is delayed, with Rs.1.51 crore unutilised.